why choose us

First received: October 07, 2022

Clinical Trial: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Study of TBio-4101 (Autologous Selected and Expanded Tumor-Infiltrating Lymphocytes [TIL]) and Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (STARLING)

Brief Summary: A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.

Read more